Literature DB >> 23969034

Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid.

Miklós Sárdy1, Dimitra Kostaki2, Rita Varga3, Ketty Peris4, Thomas Ruzicka3.   

Abstract

BACKGROUND: Direct immunofluorescence (DIF), indirect immunofluorescence (IIF), and enzyme-linked immunosorbent assay (ELISA) are used for the laboratory diagnosis of bullous pemphigoid (BP).
OBJECTIVE: The diagnostic value of DIF and IIF on rabbit and monkey esophagus or human salt-split skin and commercial ELISAs was assessed.
METHODS: This was a single-center retrospective study where 313 patients with BP were compared with 488 control subjects.
RESULTS: DIF was the most sensitive test (90.8%) whereas sensitivities for IIF on rabbit esophagus, IIF on monkey esophagus, IIF on salt-split skin, BP180 ELISA, and BP230 ELISA were 76.0%, 73.2%, 73.3%, 72.0%, and 59.0%, respectively. The sensitivity of the serologic tests was 88.8% altogether. The specificities for DIF, IIF on rabbit esophagus, IIF on monkey esophagus, IIF on salt-split skin, BP180 ELISA, and BP230 ELISA were 98%, 96.5%, 97.1%, 100%, 94.1%, and 99.2%, respectively. LIMITATIONS: The retrospective nature of study was a limitation. Correlation of diagnostic data with clinical manifestations or disease course was not possible.
CONCLUSIONS: In suspected BP, both serologic tests and DIF have to be performed because of a sensitivity issue. Although the ELISAs had a relatively low sensitivity, the serologic tests altogether almost reached the level of sensitivity of DIF. The specificities of all assays were excellent.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  BMZ; BP; CI; DIF; ELISA; IIF; basement membrane zone; bullous pemphigoid; bullous pemphigoid 180; bullous pemphigoid 230; collagen XVII; confidence interval; diagnostics; direct immunofluorescence; enzyme-linked immunosorbent assay; esophagus; immunofluorescence; indirect immunofluorescence; sensitivity; specificity

Mesh:

Substances:

Year:  2013        PMID: 23969034     DOI: 10.1016/j.jaad.2013.07.009

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  24 in total

1.  Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.

Authors:  Joost M Meijer; Gilles F H Diercks; Emma W G de Lang; Hendri H Pas; Marcel F Jonkman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

4.  Tense Bullae and Pruritus.

Authors:  Matthew D Vesely; Brianna A Olamiju; Jonathan S Leventhal
Journal:  Am Fam Physician       Date:  2020-03-01       Impact factor: 3.292

5.  A Case of Atopic Dermatitis with High Serum Levels of Anti-BP180 Antibody and Dyshidrosiform Blisters Limited to the Palms and Soles.

Authors:  Junichi Kaisho; Tetsuya Honda; Teruki Dainichi; Kenji Kabashima
Journal:  Acta Derm Venereol       Date:  2021-03-09       Impact factor: 3.875

Review 6.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 7.  Autoimmune blistering diseases in females: a review.

Authors:  Cathy Y Zhao; Dédée F Murrell
Journal:  Int J Womens Dermatol       Date:  2015-02-26

Review 8.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

Review 9.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17

10.  Diagnostic dilemma? Rethinking how to diagnose bullous pemphigoid in older adults.

Authors:  Tess N Engel; Daniel C Butler
Journal:  Int J Womens Dermatol       Date:  2020-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.